-
Pediatrix Therapeutics’ Neffy NDA Accepted by NMPA for Allergy Treatment
•
China-based Pediatrix Therapeutics has announced that the New Drug Application (NDA) for its neffy (epinephrine nasal spray) has been accepted for review by the National Medical Products Administration (NMPA). The intended indication for neffy is the emergency treatment of type I allergic reactions, including severe allergic reactions, in adults and…
-
ARS Pharmaceuticals’ Neffy Receives Market Filings in Asia-Pacific Region
•
US-based ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) has announced that market filings for its intranasal epinephrine product, neffy (epinephrine nasal spray) 2 mg, have been submitted by its licensing partners in China, Japan, and Australia. Neffy’s Role in Treating Type I Allergic ReactionsNeffy is indicated for the emergency treatment of Type…
